Coagulation Work-up
| Patient 1 | Patient 2 | Patient 3 | Reference Range | |
|---|---|---|---|---|
| Age/sex | 40/M | 63/F | 45/M | |
| Presenting problem | PE* | PE/DVT | DVT | |
| Platelets | 143,000 | 273,000 | 236,000 | |
| Factor V Leiden mutation | NP | NP | NP | |
| Prothrombin gene mutation | NP | NP | NP | |
| Activated protein S | 129 | 76 | 116 | 82% to 151% |
| Activated protein C | 78 | 11† | 72 | 65% to 122% |
| Antithrombin III activity | 71 | 112 | 66 | 85% to 130% |
| Antithrombin III antigen | 280 | 215 | 191 to 369 mg/L | |
| Anti-cardiolipin IgG | 6 | 10 | 18 | <15: − 15 to 20: ± |
| Anti-cardiolipin IgM | 13 | 15 | 11 | <12.5: − 12.5 to 20: ± |
| Lupus anticoagulant screen ratio | 1.36 | 1.50 | <1.20 | |
| Protein S antigen (total) | 144 | 65 | 153 | 72% to 152% |
| Protein C antigen | 81 | 60 | 61 | 76% to 158% |
| Factor X antigen | 52 | 98 | 70% to 140% | |
| Homocysteine | 10.9 | 11.9 | ||
| Factor IX | 66 | |||
| Factor VIII (done twice) | 276 | 239 | 247 | 50% to 150%‡ |
| 126§ | 221 | 329 |
* PE, pulmonary emboli; DVT, deep vein thrombosis; NP, not present.
† Believed to be secondary to concomitant warfarin.
‡ Percentage (%) is the same as international units/deciliter (IU/dL).
§ Performed at a different laboratory; all others done by Stony Brook University Hospital Laboratory.